MedTech Companies Successfully Funded on CrowdFundMe

Always, but especially at this time of unfavorable macroeconomic conditions, many observers (and some investors) look at equity crowdfunding with skepticism.

In reality, successful cases of funded companies are not uncommon; on the contrary, as the results achieved by equity crowdfunding also grow, the likelihood of monetization for investors increases.

The CrowdFundMe platform recently reported, for example, the cases of two Medtech companies funded in the past few years: Sempli Farma and RX Home.

Read more about the MedTech companies funded through crowdfunding campaigns, and find the latest business news of the day with the Born2Invest mobile app.

Sempli Farma is a service, launched by MedTech startup Remedio, that automates therapies with ad hoc technology

In 2021, it successfully closed its equity crowdfunding campaign. The company had raised €300,000, thanks to 93 investors, with a post-money valuation of €2 million.

At the time, the company had achieved revenues of €200,000 in 2020, with positive EBITDA.

In 2022, the startup generated revenues of more than €1,200,000, lower than the budget planned at the time of the campaign, but producing an after-tax profit of €88,000.

But the run continues: as of May 30, 2023, revenues stood at about € 800,000 (+100% year-on-year). In addition, a partnership has been established with the Alliance Healthcare Boots group pharmacy network and Apoteca Natura.

Sempli Farma automates and personalizes the preparation of therapies for patients so as to reduce errors and the resulting clinical risk. It uses a sophisticated hardware & software system that “unpacks” the medications an individual patient needs to take at a certain time of day and repackages them into a sachet.

If the patient has to take medications at different times of the day, for each time of intake Sempli Farma provides a sachet containing the relevant tablets or capsules.

The sachets are dispensed through a “smart dispenser,” which dispenses the right sachet at the predetermined time and reminds the patient with beeps and lights that it is time for intake and alerts caregivers and family members via SMS in case of missed intake.

RX Home offers home radiology and telemedicine service.

The MedTech company launched an equity crowdfunding campaign in 2020 that raised more than €200,000 from 193 investors, reaching a post-money valuation of €1.45 million.

At the time of the round, the company had just completed trials and was preparing to test the service in the Abruzzo market, involving a dozen nursing homes in the province of Chieti and Pescara.

Last year, the number of bookings rose to 2,500, double the result achieved in 2021. And the collaboration with Medicilio, which will enable the broadcaster to reach large healthcare providers, such as San Raffaele Hospital and KOS Group, is going strong.

Home imaging involves performing X-ray and ultrasound examinations directly at patients’ homes. With a doctor’s prescription, the patient books the examination online through the portal or by phone.

The radiology technician travels to the home and performs the X-ray. His stay within the home is about 30 minutes, and at the end of the examination, he clouds the image in real-time to an associated radiologist. The radiologist then produces the report and makes it available to the patient and the requesting physician within 48 hours after the examination is performed, through a link (via email and/or text message).

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.